The standalone BPC-157 protocol is a focused, lower-cost entry point for patients who want to explore peptide therapy for a specific concern, particularly gut health, mild joint issues, or general recovery support
Sulforaphane impaired immune checkpoint blockade therapy through activating NP63/PD-L1 axis in gastric cancer
Unless youve been sleeping under a rock, you likely have heard about the remarkable benefits of the new GLP-1 receptor agonist drugs like Wegovy, Victoza, Trulicity, Mounjaro, or Byetta
International Journal of Medical Sciences , 17 (4), 457470
Patients with a history of pancreatitis, symptomatic gallbladder disease, or severe gastroparesis warrant careful discussion as well, since GLP-1s slow gastric emptying and can exacerbate these conditions